Home Cart Sign in  
Chemical Structure| 58479-68-8 Chemical Structure| 58479-68-8

Structure of Platycodin D
CAS No.: 58479-68-8

Chemical Structure| 58479-68-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Platycodin D is a natural product isolated and purified from the root of Platycodon grandiflorum., which may stimulate TNF-α synthesis or inhibit degradation of TNF-α mRNA, and is an Hsp90 inhibitor which disrupting the co-chaperone interaction of Hsp90/cell division cycle protein 37 (Cdc37) and subsequently degrading multiple Hsp90 client proteins without the feedback increase of Hsp70.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Platycodin D

CAS No. :58479-68-8
Formula : C57H92O28
M.W : 1225.32
SMILES Code : O[C@@H]1[C@H](O)[C@H]([C@@H](O[C@]1(O[C@@H]2[C@@H](O)[C@H](CO[C@H]2OC([C@@]34[C@]([H])(C5=CC[C@]6([H])[C@]7(C)[C@@]([H])(CC[C@]6([C@@]5(C[C@H]4O)C)C)C([C@H]([C@H](C7)O)O[C@@]8(O[C@H](CO)[C@H]([C@@H]([C@H]8O)O)O)[H])(CO)CO)CC(C)(CC3)C)=O)O)[H])C)O[C@]9([C@H](O)[C@@H](O[C@]%10([C@H](O)[C@](O)(CO%10)CO)[H])[C@@H](CO9)O)[H]
MDL No. :MFCD09952590
InChI Key :CYBWUNOAQPMRBA-NDTOZIJESA-N
Pubchem ID :162859

Safety of Platycodin D

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Platycodin D

DNA

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
H1299 cells 0.69 μM 1 hour Inhibits HSP accumulation, thereby suppressing thermotolerance PMC8143993
Vero cells 1.19 μM 24 hours PMC8143993
Calu-3 cells 4.76 μM 24 hours To evaluate the effect of ACBI1 on SARS-CoV-2 infection, results showed that ACBI1 significantly inhibited viral replication. PMC8143993
HEK293T cells 0.72 μM 1 hour To evaluate the effect of ACBI1 on SMARCA4 protein levels in HEK293T cells, results showed that ACBI1 treatment led to a reduction in SMARCA4 protein levels. PMC8143993
Human hepatocellular carcinoma BEL-7402 cells 5–20 μmol/L 24 hours To evaluate the autophagic effect of Platycodin D on BEL-7402 cells, results showed that Platycodin D dose-dependently induced autophagy, as evidenced by formation of cytoplasmic vacuoles, increased amounts of LC3-II, and increased numbers of MDC-positive cells. PMC4816242
Human hepatocellular carcinoma BEL-7402 cells 5–20 μmol/L 24 hours To evaluate the autophagic effect of Platycodin D on BEL-7402 cells, results showed that Platycodin D dose-dependently induced autophagy, as evidenced by formation of cytoplasmic vacuoles, increased amounts of LC3-II, and increased numbers of MDC-positive cells. PMC4816242
Human hepatocellular carcinoma BEL-7402 cells 5–40 μmol/L 24, 48, 72 hours To evaluate the autophagic effect of Platycodin D on BEL-7402 cells, results showed that Platycodin D dose-dependently induced autophagy, as evidenced by formation of cytoplasmic vacuoles, increased amounts of LC3-II, and increased numbers of MDC-positive cells. PMC4816242
RAW 264.7 macrophages 100 µg/mL 48 hours Assess the impact of BDEs@lipo-SM on macrophage polarization. Results showed significant upregulation of M2 marker CD206 and downregulation of M1 marker CD86, indicating promotion of anti-inflammatory M2 macrophage proliferation. PMC11184736
Huh7 hepatocytes 1 and 10 µg/mL 48 hours Evaluate the effects of BDEs and BDEs@lipo-SM on apoptosis and inflammatory-related gene expression. Results showed significant downregulation of BAX (pro-apoptotic factor) and inflammatory markers (iNOS, IL6, IL1b, TNF-α), with BDEs@lipo-SM exhibiting stronger anti-inflammatory effects. PMC11184736
Human platelets 0, 1, 10, 20 μM 30 min Zafirlukast inhibited platelet aggregation and fibrinogen binding with an IC50 of 1.66 μM PMC6238268
Human platelets 0, 1, 10, 20 μM 15 min Zafirlukast inhibited platelet aggregation and fibrinogen binding with an IC50 of 1.66 μM PMC6238268
Human platelets 0, 1, 10, 20 μM 30 min Zafirlukast inhibited platelet aggregation and fibrinogen binding with an IC50 of 1.66 μM PMC6238268
Human platelets 0, 1, 10, 20 μM 90 min Zafirlukast inhibited platelet aggregation and fibrinogen binding with an IC50 of 1.66 μM PMC6238268
Human platelets 0, 1, 10, 20 μM 30 min Zafirlukast inhibited platelet aggregation and fibrinogen binding with an IC50 of 1.66 μM PMC6238268
Human platelets 0, 1, 10, 20 μM 30 min Zafirlukast inhibited platelet aggregation and fibrinogen binding with an IC50 of 1.66 μM PMC6238268
PC-9 10 μmol/L 24 hours PD treatment led to an increase in cytoplasmic vacuoles, suggesting the induction of autophagy. PMC11809235
A549 10 μmol/L 24 hours Evaluate cytotoxicity, showing low cytotoxicity PMC11809235
Peripheral blood mononuclear cells (PBMCs) 10 µM 72 hours Evaluate the effect of paroxetine on autophagy markers, showing that the inducibility of autophagy markers correlates with clinical treatment outcomes PMC6452809
TZM-bl cells 10 µM 48 hours Assess the ability of CRISPR-Cas9 to edit the CCR5 gene PMC6452809
A549 lung epithelial cells 5, 10, 20 µM 1-hour pretreatment followed by 24-hour LPS stimulation To investigate the inhibitory effect of PLD on LPS-induced inflammatory response. Results showed PLD significantly suppressed LPS-induced IL-6 and IL-8 production and inhibited NF-κB and IRF3 activation. PMC5206804
Primary rat microglia cells 5, 10, 20 µM 12 hours Inhibited LPS-induced production of ROS, TNF-α, IL-6, and IL-1β, and suppressed NF-κB activation PMC5767310
MDA-MB-231 cells 1.25 μM, 2.5 μM, 5 μM, 10 μM, 20 μM 48 hours Inhibits PI4KIIα activity, reduces exosome secretion PMC4075934
MCF-7 cells 1.25 μM, 2.5 μM, 5 μM, 10 μM, 20 μM 48 hours K-145 reduced nuclear S1P, almost completely blocked H3-K9ac, HIF1α associated spheroid formation, and enhanced dead cells PMC4075934

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/cA nude mice BEL-7402 xenograft tumor model Intraperitoneal injection 5 and 10 mg/kg/d Once daily for 21 days To evaluate the antitumor effect of Platycodin D on BEL-7402 xenograft tumor growth, results showed that 10 mg/kg Platycodin D significantly reduced relative tumor volume with decreased body weight. PMC4816242
C57BL/6 mice Thrombocytopenic mouse model Ex vivo treatment followed by infusion 20 μM Single treatment To evaluate the effect of PD on in vivo hemostasis and arterial thrombosis, results showed that PD significantly prolonged tail bleeding time and delayed arterial thrombus formation. PMC6238268
BALB/c nude mice Lung cancer metastasis model Intraperitoneal injection 7.5 mg/kg or 15 mg/kg 3 times per week for 3 weeks PD significantly inhibited tumor growth and migration, and its therapeutic efficacy and safety in vivo were markedly enhanced through a homologous cell delivery system. PMC11809235
BALB/c mice Vaginal irritation model Vaginal administration 250 µM Once daily for 7 consecutive days To assess the toxicity of G1-S4/PD and G2-S16/PD combinations on vaginal tissue. Results showed no significant changes or damage to the vaginal epithelium after 7 consecutive days of application. PMC6452809
Mice Non-small cell lung cancer model 7.5 mg/kg PD significantly inhibited the formation of microvessels and VM, and reduced the expression levels of VEGFA/VEGFR PMC10859558
BALB/c mice LPS-induced acute lung injury model Intraperitoneal injection 20, 40, 80 mg/kg Administered 1 hour before LPS challenge, evaluated 7 hours post-LPS To evaluate the protective effects of PLD against LPS-induced acute lung injury. Results demonstrated PLD significantly alleviated lung histopathological changes, myeloperoxidase activity, and pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) levels. PMC5206804

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

0.82mL

0.16mL

0.08mL

4.08mL

0.82mL

0.41mL

8.16mL

1.63mL

0.82mL

References

 

Historical Records

Categories